88
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.

          Related collections

          Most cited references98

          • Record: found
          • Abstract: found
          • Article: not found

          Immunoglobulin G4: an odd antibody.

          Despite its well-known association with IgE-mediated allergy, IgG4 antibodies still have several poorly understood characteristics. IgG4 is a very dynamic antibody: the antibody is involved in a continuous process of half-molecules (i.e. a heavy and attached light-chain) exchange. This process, also referred to as 'Fab-arm exchange', results usually in asymmetric antibodies with two different antigen-combining sites. While these antibodies are hetero- bivalent, they will behave as monovalent antibodies in most situations. Another aspect of IgG4, still poorly understood, is its tendency to mimic IgG rheumatoid factor (RF) activity by interacting with IgG on a solid support. In contrast to conventional RF, which binds via its variable domains, the activity of IgG4 is located in its constant domains. This is potentially a source of false positives in IgG4 antibody assay results. Because regulation of IgG4 production is dependent on help by T-helper type 2 (Th2) cells, the IgG4 response is largely restricted to non-microbial antigens. This Th2-dependency associates the IgG4 and IgE responses. Another typical feature in the immune regulation of IgG4 is its tendency to appear only after prolonged immunization. In the context of IgE-mediated allergy, the appearance of IgG4 antibodies is usually associated with a decrease in symptoms. This is likely to be due, at least in part, to an allergen-blocking effect at the mast cell level and/or at the level of the antigen-presenting cell (preventing IgE-facilitated activation of T cells). In addition, the favourable association reflects the enhanced production of IL-10 and other anti-inflammatory cytokines, which drive the production of IgG4. While in general, IgG4 is being associated with non-activating characteristics, in some situations IgG4 antibodies have an association with pathology. Two striking examples are pemphigoid diseases and sclerosing diseases such as autoimmune pancreatitis. The mechanistic basis for the association of IgG4 with these diseases is still enigmatic. However, the association with sclerosing diseases may reflect an excessive production of anti-inflammatory cytokines triggering an overwhelming expansion of IgG4-producing plasma cells. The bottom line for allergy diagnosis: IgG4 by itself is unlikely to be a cause of allergic symptoms. In general, the presence of allergen-specific IgG4 indicates that anti-inflammatory, tolerance-inducing mechanisms have been activated. The existence of the IgG4 subclass, its up-regulation by anti-inflammatory factors and its own anti-inflammatory characteristics may help the immune system to dampen inappropriate inflammatory reactions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.

            Pertussis is a highly contagious respiratory illness caused by the bacterial pathogen Bordetella pertussis. Pertussis rates in the United States have been rising and reached a 50-y high of 42,000 cases in 2012. Although pertussis resurgence is not completely understood, we hypothesize that current acellular pertussis (aP) vaccines fail to prevent colonization and transmission. To test our hypothesis, infant baboons were vaccinated at 2, 4, and 6 mo of age with aP or whole-cell pertussis (wP) vaccines and challenged with B. pertussis at 7 mo. Infection was followed by quantifying colonization in nasopharyngeal washes and monitoring leukocytosis and symptoms. Baboons vaccinated with aP were protected from severe pertussis-associated symptoms but not from colonization, did not clear the infection faster than naïve animals, and readily transmitted B. pertussis to unvaccinated contacts. Vaccination with wP induced a more rapid clearance compared with naïve and aP-vaccinated animals. By comparison, previously infected animals were not colonized upon secondary infection. Although all vaccinated and previously infected animals had robust serum antibody responses, we found key differences in T-cell immunity. Previously infected animals and wP-vaccinated animals possess strong B. pertussis-specific T helper 17 (Th17) memory and Th1 memory, whereas aP vaccination induced a Th1/Th2 response instead. The observation that aP, which induces an immune response mismatched to that induced by natural infection, fails to prevent colonization or transmission provides a plausible explanation for the resurgence of pertussis and suggests that optimal control of pertussis will require the development of improved vaccines.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Duration of immunity against pertussis after natural infection or vaccination.

              Despite decades of high vaccination coverage, pertussis has remained endemic and reemerged as a public health problem in many countries in the past 2 decades. Waning of vaccine-induced immunity has been cited as one of the reasons for the observed epidemiologic trend. A review of the published data on duration of immunity reveals estimates that infection-acquired immunity against pertussis disease wanes after 4-20 years and protective immunity after vaccination wanes after 4-12 years. Further research into the rate of waning of vaccine-acquired immunity will help determine the optimal timing and frequency of booster immunizations and their role in pertussis control.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                03 July 2019
                2019
                : 10
                : 1344
                Affiliations
                [1] 1Department of Surgical and Biomedical Sciences, Paediatric Clinic, Università degli Studi di Perugia , Perugia, Italy
                [2] 2Department of Infectious Diseases, Istituto Superiore di Sanità , Rome, Italy
                [3] 3Immunisation and Countermeasures Division, Public Health England–National Infection Service , London, United Kingdom
                [4] 4Institute of Biomedicine, University of Turku , Turku, Finland
                [5] 5Department of Medical Microbiology, Capital Medical University , Beijing, China
                [6] 6Department of Infectious Disease Epidemiology, The Vaccine Confidence Project TM, London School of Hygiene & Tropical Medicine , London, United Kingdom
                [7] 7Division of Pediatric Infectious Diseases, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago , Chicago, IL, United States
                [8] 8Children's Hospital, Helios HSk , Wiesbaden, Germany
                [9] 9Department of Pediatrics, University Medicine , Mainz, Germany
                [10] 10Department of Pediatrics, Vall d'Hebron University Hospital , Barcelona, Spain
                [11] 11School of Medicine-Germans Trias i Pujol University Hospita, Universidad Autónoma de Barcelona , Barcelona, Spain
                [12] 12Retired, Neuilly-sur-Seine, France
                [13] 13School of Medicine, College of Health and Medicine, University of Tasmania , Hobart, TAS, Australia
                [14] 14School of Health and Biomedical Science, RMIT University , Melbourne, VIC, Australia
                [15] 15Department of Immunology and Pathology, Monash University , Melbourne, VIC, Australia
                [16] 16Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong , Hong Kong, China
                [17] 17Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu , Tartu, Estonia
                [18] 18Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, TN, United States
                [19] 19Microbiology and Mycology Program, Faculty of Medicine, Institute of Immunology and Immunotherapy, University of Chile , Santiago, Chile
                [20] 20Retired, Milan, Italy
                Author notes

                Edited by: Luciana Leite, Instituto Butantan, Brazil

                Reviewed by: Camille Locht, Institut National de La Santé et de la Recherche Médicale (INSERM), France; Carmen Alvarez-Dominguez, Instituto de Investigación Marques de valdecilla (IDIVAL), Spain; Kingston H. Mills, Trinity College Dublin, Ireland

                *Correspondence: Susanna Esposito susanna.esposito@ 123456unimi.it

                This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2019.01344
                6616129
                31333640
                36ad987e-3b57-4823-b39d-217c4b66412d
                Copyright © 2019 Esposito, Stefanelli, Fry, Fedele, He, Paterson, Tan, Knuf, Rodrigo, Weil Olivier, Flanagan, Hung, Lutsar, Edwards, O'Ryan and Principi.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 24 February 2019
                : 28 May 2019
                Page count
                Figures: 2, Tables: 0, Equations: 0, References: 115, Pages: 11, Words: 9816
                Categories
                Immunology
                Review

                Immunology
                acellular pertussis vaccine,bordetella pertussis,pertussis,whole-cell pertussis vaccine,pertussis prevention

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content100

                Cited by58

                Most referenced authors1,014